Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Approves Insurance Coverage For Three Diagnostics

This article was originally published in PharmAsia News

Executive Summary

The Central Social Medical Insurance Agency (Chuikyo) April 21 approved insurance coverage for three diagnostic items. The council approved price listing for MESACUP anti-RNA polymerase III test for systemic scleroderma at ¥1,700, citing a high sensitivity in systemic scleroderma diagnosis and efficacy compared to current diagnostics. The test is developed by Medical and Biological Laboratories. In addition, two fatty acid binding protein diagnostics for acute myocardial infarction, developed separately by DS Pharma Biomedical and Biolinks, were priced at ¥1,500. Both diagnostics are able to obtain rapid results compared to current testing. (Click here for more - Japanese language)"Chuikyo Approves Medical Insurance For Three Diagnostics Including Systemic Scleroderma Testing" - Chemical Daily (4/14/2010)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC074944

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel